Genetic Risk and Coronary Artery Calcium in Personalizing Antihypertensive Treatment: A Pooled Cohort Analysis.

doi:10.1016/j.mayocp.2023.12.020

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genetic Risk and Coronary Artery Calcium in Personalizing Antihypertensive Treatment: A Pooled Cohort Analysis.

Mayo Clinic proceedings - 1 Sept 2024

Shetty Naman S, Gaonkar Mokshad, Pampana Akhil, Patel Nirav, Irvin Marguerite R, Lin Henry J, Guo Xiuqing, Rich Stephen S, Rotter Jerome I, Budoff Matthew J, Li Peng, Arora Garima, Arora Pankaj

Abstract excerpt

OBJECTIVE: To assess the role of the systolic blood pressure polygenic risk score (SBP-PRS) in antihypertensive treatment initiation and its comparative efficacy with coronary artery calcium (CAC) scores. PATIENTS AND METHODS: This retrospective cohort study included participants with whole genome sequencing data who underwent CAC scanning between 1971 and 2008, were free of prevalent cardiovascular disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Blood Pressure

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coronary Artery Disease

Share to Coronary Vessels

Share to Hypertension

Share to Precision Medicine

Share to Risk Assessment

Share to Vascular Calcification

Source

Open in PubMed

Identifiers

PMID: 39115511
DOI: 10.1016/j.mayocp.2023.12.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.